76 related articles for article (PubMed ID: 21112770)
21. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
Ladenstein R; Lambert B; Pötschger U; Castellani MR; Lewington V; Bar-Sever Z; Oudoux A; Śliwińska A; Taborska K; Biassoni L; Yanik GA; Naranjo A; Parisi MT; Shulkin BL; Nadel H; Gelfand MJ; Matthay KK; Park JR; Kreissman SG; Valteau-Couanet D; Boubaker A
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):292-305. PubMed ID: 28940046
[TBL] [Abstract][Full Text] [Related]
22. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
23. Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.
Berthold F; Spix C; Kaatsch P; Lampert F
Paediatr Drugs; 2017 Dec; 19(6):577-593. PubMed ID: 28786082
[TBL] [Abstract][Full Text] [Related]
24. Improved outcome of
Corroyer-Dulmont A; Falzone N; Kersemans V; Thompson J; Allen DP; Able S; Kartsonaki C; Malcolm J; Kinchesh P; Hill MA; Vojnovic B; Smart SC; Gaze MN; Vallis KA
Radiother Oncol; 2017 Sep; 124(3):488-495. PubMed ID: 28595752
[TBL] [Abstract][Full Text] [Related]
25. A single center clinical analysis of children with high-risk neuroblastoma.
Tian X; Cao Y; Wang J; Yan J; Tian Y; Li Z; Wang H; Duan X; Jin Y; Zhao Q
Oncotarget; 2017 May; 8(18):30357-30368. PubMed ID: 28423674
[TBL] [Abstract][Full Text] [Related]
26.
Yue ZX; Huang C; Gao C; Xing TY; Liu SG; Li XJ; Zhao Q; Wang XS; Zhao W; Jin M; Ma XL
Cancer Cell Int; 2017; 17():43. PubMed ID: 28367105
[No Abstract] [Full Text] [Related]
27. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.
Applebaum MA; Vaksman Z; Lee SM; Hungate EA; Henderson TO; London WB; Pinto N; Volchenboum SL; Park JR; Naranjo A; Hero B; Pearson AD; Stranger BE; Cohn SL; Diskin SJ
Eur J Cancer; 2017 Feb; 72():177-185. PubMed ID: 28033528
[TBL] [Abstract][Full Text] [Related]
28. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.
Formicola D; Petrosino G; Lasorsa VA; Pignataro P; Cimmino F; Vetrella S; Longo L; Tonini GP; Oberthuer A; Iolascon A; Fischer M; Capasso M
J Transl Med; 2016 May; 14(1):142. PubMed ID: 27188717
[TBL] [Abstract][Full Text] [Related]
29. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma.
Lakoma A; Barbieri E; Agarwal S; Jackson J; Chen Z; Kim Y; McVay M; Shohet JM; Kim ES
Cell Death Discov; 2015; 1():15026-. PubMed ID: 26998348
[TBL] [Abstract][Full Text] [Related]
30. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
31. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
32. Orbital Metastasis Is Associated With Decreased Survival in Stage M Neuroblastoma.
Harreld JH; Bratton EM; Federico SM; Li X; Grover W; Li Y; Kerr NC; Wilson MW; Hoehn ME
Pediatr Blood Cancer; 2016 Apr; 63(4):627-33. PubMed ID: 26599346
[TBL] [Abstract][Full Text] [Related]
33. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.
Ioka A; Inoue M; Yoneda A; Nakamura T; Hara J; Hashii Y; Sakata N; Yamato K; Tsukuma H; Kawa K
J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355
[TBL] [Abstract][Full Text] [Related]
34. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.
Mody RJ; Wu YM; Lonigro RJ; Cao X; Roychowdhury S; Vats P; Frank KM; Prensner JR; Asangani I; Palanisamy N; Dillman JR; Rabah RM; Kunju LP; Everett J; Raymond VM; Ning Y; Su F; Wang R; Stoffel EM; Innis JW; Roberts JS; Robertson PL; Yanik G; Chamdin A; Connelly JA; Choi S; Harris AC; Kitko C; Rao RJ; Levine JE; Castle VP; Hutchinson RJ; Talpaz M; Robinson DR; Chinnaiyan AM
JAMA; 2015 Sep; 314(9):913-25. PubMed ID: 26325560
[TBL] [Abstract][Full Text] [Related]
35. Detection of tumor ALK status in neuroblastoma patients using peripheral blood.
Combaret V; Iacono I; Bellini A; Bréjon S; Bernard V; Marabelle A; Coze C; Pierron G; Lapouble E; Schleiermacher G; Blay JY
Cancer Med; 2015 Apr; 4(4):540-50. PubMed ID: 25653133
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral diversity of telomere length in individual neuroblastoma tumors.
Pezzolo A; Pistorio A; Gambini C; Haupt R; Ferraro M; Erminio G; De Bernardi B; Garaventa A; Pistoia V
Oncotarget; 2015 Apr; 6(10):7493-503. PubMed ID: 25595889
[TBL] [Abstract][Full Text] [Related]
37. Epidemiological and clinical characteristics of neuroblastoma in southern iran.
Bordbar M; Tasbihi M; Kamfiroozi R; Haghpanah S
Iran J Ped Hematol Oncol; 2014; 4(3):89-96. PubMed ID: 25254086
[TBL] [Abstract][Full Text] [Related]
38. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy.
Applebaum MA; Henderson TO; Lee SM; Pinto N; Volchenboum SL; Cohn SL
Pediatr Blood Cancer; 2015 Jan; 62(1):128-33. PubMed ID: 25251613
[TBL] [Abstract][Full Text] [Related]
39. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.
Kushner BH; Modak S; Kramer K; LaQuaglia MP; Yataghene K; Basu EM; Roberts SS; Cheung NK
Cancer; 2014 Jul; 120(13):2050-9. PubMed ID: 24691684
[TBL] [Abstract][Full Text] [Related]
40. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.
Morgenstern DA; London WB; Stephens D; Volchenboum SL; Hero B; Di Cataldo A; Nakagawara A; Shimada H; Ambros PF; Matthay KK; Cohn SL; Pearson AD; Irwin MS
J Clin Oncol; 2014 Apr; 32(12):1228-35. PubMed ID: 24663047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
